OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.98% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.93%, a 4.61% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.12%, a 7.85% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.82%, a 9.77% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.48%, a 105.92% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.07%, a 4.09% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.91%, a 7.42% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.64%, a 82.91% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.99%, a 109.47% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 3.98% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 3.93% 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 4.07% 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | 4.08% 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 4.12% 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | 3.91% 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | 3.92% 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 3.93% 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | 3.82% 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 3.64% 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | 3.56% 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 3.48% 10-Q · filed 2024-08-06 | 3.52% 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | 3.48% 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 1.99% 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | 1.89% 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | 1.81% 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 1.69% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 0.95% 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | 0.63% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 0.62% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 0.43% 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 0.51% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |